Atlas Trials

Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer

Clinical trial NCT07068516 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07068516
Sponsor
Xiangdong Cheng
Status
NOT_YET_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Gastric Cancer Stage
Start date
2025-07-20
Primary completion
2027-06-30
Enrollment
470

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.